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Fcg Receptor±Initiated Signaling
When once your point of view is changed, the very thing ADCC mediated by NK cells is initiated by engagement
which was so damning becomes a clue to the truth. of low-affinity FcgRIIIA by the Fc portion of antibodies
ÐSherlock Holmes bound to cell-associated antigens. FcgRIIIA on human
NK cells is a multimeric receptor complex consisting of
the ligand-binding a subunit (CD16), which associatesNatural killer (NK) cells are a subpopulation of phenotyp-
ically identifiable lymphocytes (CD161, CD32, sIg2) that noncovalently with homodimers or heterodimers of z
and g (Figure 1) (Anderson et al., 1989; Lanier et al.,can mediate the lysis of certain tumor cells and virus-
infected cells and that can secrete certain cytokines 1989; Orloff et al., 1990; Kurosaki et al., 1991). Although
none of the subunits of the receptor complex possessesuponactivation (e.g., g-interferon, tumor necrosis factor,
granulocyte/macrophage colony-stimulating factor, and intrinsic kinase activity, conserved immunoreceptor ty-
rosine-based activation motifs (ITAMs) (consensus aminomacrophage colony-stimulating factor) (Trinchieri, 1989,
1995). These biological responses enable NK cells to acid sequence YXXL-X(6±8)-YXXL) in the z and g subunits
are critical for the rapid generation of intracellular sec-provide resistance against infectious microorganisms,
control malignant growth, modulate other immune cells, ond messengers (Reth, 1989; Cambier, 1995). The struc-
tural context of the ITAMs in the z-g±containing humanand regulate hematopoietic cell differentiation. The exe-
cution of these effector functions is initiated when re- FcgRIII complex is different from all z-g±containing
multisubunit immune recognition receptors. Althoughceptors on NK cells bind to specific soluble or cell-
associated ligands. The translation of these recognition the TCR complex can express both z and g, additional
subunits in the complex (CD3-g, CD3-d, and CD3-e) con-events into intracellular biochemical signals regulates
NK cell functional responses. tain ITAMs, and these motifs may quantitatively or quali-
tatively alter the signals from the TCR (Weiss and Litt-It is tempting to suggest that NK cells are simply
another type of lymphocyte bearing multisubunit im- man, 1994; Paolini et al., 1995; Wange and Samelson,
1996). The high-affinity receptor for immunoglobulin Emune recognition receptors and that their signaling
mechanisms are therefore likely to recapitulate those (FceRI) has only g homodimers with a signal-amplifying
ITAM-containing b chain (Ravetch and Kinet, 1991).described for T or B lymphocytes. This generalist view
is also fueled by the recognition that NK cells and T Although structural homology among the various
ITAM-containing subunits has permitted investigatorscells share a common progenitor (Spits et al., 1995) and
that many NK cell surface receptors are expressed on to demonstrate some degree of functional overlap in
experimental systems, key differences in signaling andsubsets of T cells (Trinchieri, 1989). Yet a series of recent
experimental observations highlights the inadequacy of functional responses have been observed. These differ-
ences were recently underscored by the demonstrationsthis derivative perspective. For example, whereas the
Src-family tyrosine kinase Lck and the cell surface tyro- that different ITAMs can bind different intracellular sig-
naling molecules (including ZAP-70, Syk, phosphlipasesine phosphatase CD45 are essential for T cell receptor
(TCR)±initiated signaling, these molecules, which are C-g1 [PLC-g1], and phosphatidylinositol 3-kinase [PI3K])
(Exley et al., 1994; Cambier and Johnson, 1995; Isakovalso expressed by normal NK cells, are not required for
NK cell Fc receptor (FcR)±mediated killing or natural et al., 1995; Osman et al., 1996). This heterogeneity sug-
gests the potential for different ITAM-containing sub-cytotoxicity (Molina et al., 1992; Wen et al., 1995; van
Oers et al., 1996; Yamada et al., 1996). Similarly, the units to couple to separate signaling pathways. In NK
cells, the principal focus is on the ITAM-containing gSyk-family tyrosine kinase ZAP-70, which is expressed
by both T cells and NK cells, is required for TCR-initiated subunit, since murine FcgRIII contains only g-g homodi-
mers (Kurosaki and Ravetch, 1989) and since g2/2 mice,signaling but not for NK cell cytotoxic function (Chen
et al., 1994; Negishi et al., 1995). In addition, recent but not z2/2 mice, have lost their ability to mediate ADCC
(Liu et al., 1993; Takai et al., 1994).observations have highlighted the central role for novel
major histocompatibilitycomplex (MHC)±recognizing in- One of the earliest detectable signaling events follow-
ing FcgRIII ligation is increased tyrosine kinase activityhibitory receptors in determining the capacity of NK cells
to initiate cellular activation (Ljunggren and Karre, 1990; (Einspahr et al., 1991; O'Shea et al., 1991; Vivier et al.,
1991). Indeed, pharmacological inhibition of this proteinLeibson, 1995; Lanier and Phillips, 1996; Moretta et al.,
1996; Brown et al., 1997; Colonna, 1997; Long et al., tyrosine kinase (PTK) activation blocks the development
of ADCC (Einspahr et al., 1991; O'Shea et al., 1992).1997; Raulet et al., 1997; Renard et al., 1997).
This minireview focuses on a description and analysis Two specific families of PTKs have been implicated in
proximal signaling initiated by FcgRIII ligation: the Src-of the signaling mechanisms that critically influence the
specialized cytotoxic function of NK cells: FcgRIII-initi- family PTKs (which in NK cells include Lck, Fyn, Yes,
and Lyn) and the Syk-family PTKs (which in NK cellsated antibody-dependent cellular cytotoxicity (ADCC)
and natural killing. Information is provided to suggest include ZAP-70 and Syk) (Figure 1). Lck is detectable in
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Figure 1. FcgRIII-Initiated Signaling Events
MAPK, mitogen-activated protein kinase; IP3,
inositol-1,4,5-trisphosphate; DAG, sn-1,2-
diacylglycerol.
anti-FcgRIII immunoprecipitates, and crosslinking of the subunit and a p110 catalytic subunit, and FcgR cross-
linking induces increased PI3K activity (Kanakaraj et al.,FcR increases the in vitro catalytic activity of Lck (Cone
et al., 1993; Pignata et al., 1993; Salcedo et al., 1993). 1994). The critical role of PI3K in ADCC is highlighted by
the demonstration that wortmannin, a fungal metaboliteIn addition, FcR stimulation in NK cells induces rapid
tyrosine phosphorylation of both ZAP-70 and Syk (Vivier that inhibits PI3K by binding irreversibly to its p110 cata-
lytic subunit, blocks FcR-initiated killing (Bonnema etet al., 1993; Stahls et al., 1994). Similar to TCR-initiated
signaling, Lck can play a regulatory role in the FcR- al., 1994). FcR stimulation also induces the activation
of Ras (associated with Shc and p36 tyrosine phosphor-induced tyrosine phosphorylation and enhanced cata-
lytic activity of Syk-family PTKs (Ting et al., 1995). ylation) (Galandrini et al., 1996), Vav (Xu and Chong,
1996), PLA2, Erk-2 (Milella et al., 1997), nuclear factorHowever, as noted earlier, FcR-initiated signaling
does not require Lck or Fyn. This could be due to redun- of activated T cells-p, and nuclear factor of activated T
cells-c (Aramburu et al., 1995). These second messen-dancy by other Src-family members, but investigations
to date have not shown that other Src-family PTKs cou- gers are believed to regulate cytoskeletal changes and
transcriptional events following receptor ligation.ple to the FcgRIIIA. Rather, recent findings obtained in
other types of hematopoietic cells suggest that Syk (but
not ZAP-70) has the potential to tyrosine phosphorylate
ITAM-containing receptors and to initiate downstream Activating Signals That Regulate
Natural Cytotoxicityactivation in a Src-family±independent manner (Chu et
al., 1996; Pao and Cambier, 1997; Zoller et al., 1997). ªNatural cytotoxicityº refers to the capacity of NK cells
to mediate antitumor or antiviral immunity without priorThese findings are also consistent with the observation
that CD45, a critical regulator of Src-family PTKs, is not sensitization and in the absence of antibody. In contrast
to the clear molecular definition of the receptor thatrequired for signaling initiated by multisubunit immune
recognition receptors that are coupled to Syk (Chu et initiates ADCC, attempts to identify a single triggering
receptor for natural cytotoxicity have been unsuccess-al., 1996; Pao and Cambier, 1997). Therefore, the poten-
tial for the ITAM-containing g subunit of the FcR complex ful. In fact, the emerging picture suggests that a variety
of activating cellular receptors may influence the abilityin human and murine NK cells to couple to Syk may
account for its ability to mediate ADCC in the absence of NK cells to respond to cells and soluble mediators
in their microenvironment (reviewed by Lanier, 1997).of Lck, Fyn, CD45, or ZAP-70.
The FcR-initiated proximal activation of PTKs in NK A recurring theme in recent reports is that molecules
traditionally thought of as ªadhesionº or ªcostimulatoryºcells modifies multiple downstream signaling elements
that contribute to the development of ADCC and cyto- receptors on other hematopoietic cell types may, alone
or in concert with other cell surface molecules, triggerkine secretion (Figure 1). Both PLC-g1 and PLC-g2 are
tyrosine phosphorylated following FcgRIII ligation (Az- NK cell activation. These include a variety of integrins
(e.g., a4b1, a5b1, LFA-1, and avb3) (Gismondi et al., 1995;zoni et al., 1992; Ting et al., 1992). Activated PLC-g
cleaves membrane phosphoinositides to generate inosi- Rabinowich et al., 1995a, 1995b; Helander et al., 1996;
Rabinowich et al., 1996), CD2 (Siliciano et al., 1985),tol-1,4,5-trisphosphate and sn-1,2-diacylglycerol, re-
sulting in increased intracellular free calcium concentra- CD44 (Galandrini et al., 1994; Sconocchia et al., 1994),
and CD69 (Moretta et al., 1991). In addition, receptorstion ([Ca21]i) and protein kinase C, respectively. The
elevated [Ca21]i is required for the granule release in- such as NKR-P1 (Chambers et al., 1989; Ryan et al.,
1995), DNAX accessory molecule-1 (Shibuya et al.,volved in the delivery of the lethal hit. Another down-
stream effector that requires proximal PTK activation is 1996), NK-TR (Frey et al., 1991), and Lag3 (Miyazaki et
al., 1996) have been implicated as contributors to thePI3K. PI3K is a lipid kinase consisting of a p85 regulatory
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development of certain forms of NK cell±mediated kill- that lacks an ITIM (Chang et al., 1995; Lazetic et al.,
ing. Finally, some NK cells express on their cell surface 1996; Carretero et al., 1997; Houchins et al., 1997). To
activating isoforms of human killer cell inhibitory recep- date, ITAM-containing associated subunits have not
tors (KIR), human CD94/NKG2, and murine Ly49 (Mason been identified for CD94/NKG2-C, but the signals de-
et al., 1994; Moretta et al., 1995; Perez-Villar et al., 1995; rived from this receptor complex include proximal acti-
Biassoni et al., 1996; Bottino et al, 1996; Brumbaugh et vation of PTKs (Lck, ZAP-70, and Syk) and PLC-g, inositol
al., 1996; Mandelboim et al., 1996; Mason et al., 1996; phosphate release, and elevations in [Ca21]i (Perez-Villar
Carretero et al., 1997; Houchins et al., 1997). These acti- et al., 1995; Brumbaugh et al., 1996). The ITAM-con-
vating molecules differ from their MHC-recognizing in- taining z and g subunits are not tyrosine-phosphorylated
hibitory counterparts (discussed in the next section) by following CD94/NKG2-C ligation, suggesting the utiliza-
lacking inhibitory motifs in their short cytoplasmic do- tion of separate transducing subunits.
mains and by potentially associating with additional Although there are striking similarities between the
subunits that may transduce activating signals to the intracellular signaling events described above for natu-
cell interior. Whether these receptors participate in MHC ral cytotoxicity and those taking place during FcgRIII-
recognition or contribute to natural cytotoxicity remains initiated signaling, there are some signaling elements
to be determined. that are used differentially during natural killing com-
Given the number of potential receptors involved in pared with ADCC. For example, whereas natural cyto-
natural cytotoxicity, thekilling of different targets is likely toxicity against prototypic NK-sensitive targets, such as
to be regulated at least in part by different second mes- K562, can be controlled by protein kinase C±dependent
sengers. This heterogeneity must be kept in mind in the PI3K-independent pathways, FcR-initiated granule re-
attempt to formulate generalizable conclusions. How- lease and killing can be regulated by protein kinase
ever, studies done to date have consistently demon- C±independent PI3K-dependent pathways (Bonnema et
strated that PTK activation, PLC-catalyzed release of al., 1994). In addition, as noted above, given the number
phosphoinositides, and elevations in [Ca21]i are early of potential receptors involved in natural cytotoxicity,
and requisite events during the development of most the killing of different targets is likely toelicit qualitatively
forms of natural cytotoxicity (reviewed by Brumbaugh or quantitatively different signals. For example, certain
et al., 1997). The similarity of these signaling events virus-infected and LAK (lymphokine-activated killer)±
with those used during FcgRIII-dependent killing invites
sensitive targets trigger NK cell-mediated killing in the
speculation that ITAM-containing subunits coupled to
absence of detectable PLC-dependent calcium signal-
specific proximal PTKs may also play a role in the devel-
ing (Zanovello et al., 1989; Paya et al., 1990). Additional
opment of natural cytotoxicity. If so, z and g are not the
progress in defining the relevant signals that critically
ITAM-containing receptors, since NK cells lacking these
regulate the development of natural cytotoxicity will de-
subunits can mediate natural cytotoxicity (Liu et al.,
pend on clear molecular identification of the involved1993; Takai et al., 1994). As is the case for ADCC, Lck
triggering receptors.and ZAP-70 are not required for natural killing (Chen et
al., 1994; Negishi et al., 1995; Wen et al., 1995; van Oers
et al., 1996). To date, no information is available as to Inhibition Induced by MHC-Recognizing Receptors
whether Syk might play a key regulatory role in natural
Although many studies to date have focused on defining
cytotoxicity.
the signaling events that induce NK cell activation, thereParallels with FcR-initiated signaling are directly ap-
is increasing agreement that the capacity of NK cells toparent in the killing initiated by activating forms of the
mediate killing or to secrete cytokines is determinedreceptors whose extracellular domains are homologous
by a balance between positive and negative regulatoryto the MHC-recognizing inhibitory receptors (i.e., KIR,
events. In particular, there has been broad interest inLy49, CD94/NKG2). For example, human killer cell acti-
recent data showing that receptor-mediated recognitionvating receptors (KARs) have extracellular domains ho-
of MHC class I complexes on target cells can block NKmologous to the immunoglobulin superfamily KIRs, but
cell and T cell cytotoxic function in vitro and in vivo. Thetheir short cytoplasmic tails do not contain the immuno-
inhibitory MHC-recognizing receptors defined thus farreceptor tyrosine-based inhibitory motifs (ITIMs) that are
include human KIR (two or three immunoglobulin super-responsible for KIR inhibitory function. Instead, KARs
family domains in their extracellular regions), humanexpress a single lysine residue within their transmem-
CD94/NKG2 (both subunits are members of the C-typebrane domains, similar to the charged amino acid resi-
lectin superfamily), and murine Ly49 (type II disulfide-due in the transmembrane portion of the ligand-binding
linked dimeric integral membrane proteins with homol-subunits of multiple immune recognition receptor com-
ogy to the C-type lectin superfamily) (Figure 2) (reviewedplexes (e.g., TCR ab, FcgRIIIa, and FceRIa). In each
by Brown et al., 1997; Colonna, 1997; Lanier, 1997; Longcase, this residue is required for assembly with their
and Wagtmann, 1997). Different MHC-recognizing re-ITAM-containing subunits. A set of disulfide-linked di-
ceptors have differing specificities for distinct familiesmers have recently been biochemically identified in KAR
of MHC class I molecules, and clonal subpopulationsimmunoprecipitates, and the tyrosine phosphorylation
of NK cells differ in their expression of specific MHC-of these KAR-associated polypeptides is presumed to
recognizing receptors. When tumor cells or virus-infectedinitiate intracellular signaling (Olcese et al., 1997). Simi-
cells have down-regulated their surface class I expres-larly, the activating form of the C-type lectin CD94/NKG2
sion, they potentially enhance their susceptibility to NKcomplex consists of a disulfide-linked heterodimer
cell-mediated killing (Karre et al., 1986; Kaufman, et al.,made up of a CD94 subunit (seven±amino acid cyto-
plasmic tail) and an NKG2 family member (e.g., NKG2-C) 1992; Farrell et al., 1997; Reyburn et al., 1997). However,
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Figure 2. Sequential Model of Inhibitory Sig-
naling from MHC-Recognizing Receptors
(1) Ligation of the MHC-recognizing receptors
induces Src-family PTK to phosphorylate the
tyrosine residues in the conserved ITIMs. (2)
The SH2 domain±containing tyrosine phos-
phatase, SHP-1, is recruited to the phosphor-
ylated ITIMs. (3) Coaggregation of the receptor-
associated SHP-1 with activating receptors
results in inhibition of PTK-dependent NK cell
activation.
it should be emphasized that certain targets with de- importance of the SHP-1 association is highlighted by
the demonstration that overexpression of a catalyticallycreased MHC class I arenot sensitive to NK cytotoxicity,
suggesting that the removal of inhibitory signals without inactive form of SHP-1 (acting as a dominant negative)
reverses the inhibitory effects of KIR ligation on bothconcurrent recognition of a triggering epitope may be
insufficient to initiate NK cellular activation. Conversely, natural killing and ADCC (Binstadt et al., 1996; Burshtyn
et al., 1996). Importantly, SHIP, an SH2-domain con-certain targets are such potent activators of NK cells
that MHC expression does not inhibit their killing (Lanier taining inositol phosphatase that binds to the ITIM in
the cytoplasmic tail of the inhibitory FcgRIIB receptoret al., 1997).
Despite the structural heterogeneity in the extracellu- (Chacko et al., 1996; Ono et al., 1996), does not appear
to bind to tyrosine-phosphorylated KIR (Burshtyn et al.,lar, MHC-recognizing portion of the various inhibitory
receptors, emerging evidence suggests that a common 1996; Vely et al., 1997). This suggests that although the
MHC-recognizing receptors may depend on SHP-1 forinhibitory mechanism may be used in each case (Bin-
stadt et al., 1997; Renard et al., 1997). This mechanism their inhibition, other ITIM-containing receptors (e.g.,
FcgRIIB) may target other intracellular signaling mecha-includes (1) tyrosine phosphorylation of a conserved
ITIM sequence in the cytoplasmic tail of the receptors; nisms (Scharenberg and Kinet, 1996).
Information is just beginning to emerge as to how(2) association of the receptor with the SH2 domain±
containing tyrosine phosphatase SHP-1; and (3) SHP- SHP-1±associated MHC-recognizing receptors might
inhibit NK cell activation. Specifically, the tyrosine phos-1±dependent inhibition of proximal tyrosine kinases
(Figure 2). The cytoplasmic tail of each inhibitory MHC- phorylation of key proximal substrates is interrupted. In
the case of ADCC, FcR coengagement with either KIRrecognizing receptor contains one or two copies of the
consensus sequence [I,V]xYxx[L,V]. The [I,V] amino or CD94/NKG2-A inhibits the tyrosine phosphorylation
of both the z and g subunits, ZAP-70, Syk, and PLC-gacids at the 22 position upstream of the tyrosine in
this ITIM sequence differentiates the YXXL sequence of (Binstadt et al., 1996; Brumbaugh et al., 1996). In the
case of natural cytotoxicity, MHC recognition by KIRinhibitory receptors from the YxxL in the ITAM-con-
taining activating multisubunit immune recognition re- inhibits the tyrosine phosphorylation of select sub-
strates and blocks the formation of a complex con-ceptors (Burshtyn et al., 1997; Vely et al., 1997). The
crosslinking of the MHC-recognizing inhibitory recep- taining tyrosine-phosphorylated p36 and PLC-g (Vali-
ante et al., 1996). For both modes of NK cell±mediatedtors induces the phosphorylation of the tyrosine residue
in the ITIM (Binstadt et al., 1996; Burshtyn et al., 1996). cytotoxicity, the proximal effects on PTK activation re-
sult in inhibition of inositol phosphate release and cal-Genetic analysis suggests that the Src-family PTK Lck
plays a central role in this process for human KIR (Bin- cium mobilization (Kaufman et al., 1995; Brumbaugh
et al, 1996). The biochemical pattern of KIR-mediatedstadt et al.,1996). For example, no tyrosine phosphoryla-
tion is observed following ligation of KIR expressed in inhibition is consistent with potential targeting by SHP-1
of a variety of signaling proteins, including z, g, Lck,the Lck-deficient Jurkat line JCaM1. KIR tyrosine phos-
phorylation is efficiently restored by reexpression of ZAP-70, or Syk. Interestingly, natural cytotoxicity does
not depend on either z or g, indicating either that ITAMwild-type Lck but not by expression of other Src-family
members such as Fyn, c-Src, or Lyn. dephosphorylation does not contribute to the inhibition
of this process by KIR-associated SHP-1 or that an asA common feature of all the inhibitory MHC-recogniz-
ing receptors is the recruitment of the tyrosine phospha- yet unidentified z/g homolog is targeted during natural
killing. Alternatively, proximal Src-family or Syk-familytase SHP-1 to the tyrosine phosphorylated ITIMs (Figure
2) (Binstadt et al., 1996; Burshtyn et al., 1996; Campbell PTK could be the physiological targets for SHP-1. How-
ever, since NK cells deficient for Lck or ZAP-70 canet al., 1996; Fry et al., 1996; Olcese et al., 1996; Houchins
et al., 1997; Nakamura et al., 1997). SHP-1 contains two mediate both forms of NK cell±mediated killing, they are
unlikely to be the sole targets for SHP-1. In contrast,amino-terminal SH2 domains and a carboxy-terminal
catalytic domain. The phosphotyrosine-dependent as- depending on whether Syk can function in NK cells in
an Lck-independent manner and whether Syk activationsociation of the inhibitory receptors with SHP-1 appears
to be mediated by the more carboxy-terminal SH2 do- is critical for natural killing, Syk could be a candidate
for SHP-1-mediated inhibition. Thus, the question ofmain of SHP-1 (Burshtyn et al., 1996). The functional
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what signaling molecule(s) are direct in vivo substrates occurring during the development of a cytotoxic re-
sponse. Future advances will depend in part on theof KIR-associated SHP-1 remains open.
It is important that all of the data to date suggest that molecular identification of the involved receptors and
second messengers and on the development of experi-the MHC-recognizing receptors exert their inhibitory ef-
fect on NK cellular activation only when they are coag- mental models for genetically manipulating the signaling
elements. It will remain important to investigate bothgregated with activating receptors. This is presumably
due to the requirement for the KIR-associated SHP-1 activating and inhibitory signaling pathways, since the
emerging theme is that the balance of these opposingto be brought into physical proximity with its substrates
in the activation complex. As a result, cell surface ex- forces determines the functional outcome of an NK cell's
interaction with its target.pression of KIR does not intrinsically raise the threshold
for NK cell activation. Furthermore, the inhibition in-
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